Caris Life Sciences, Inc. Overview
Pro stress-test →Caris Life Sciences is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The company is a rapidly-growing market leader in precision oncology lab testing, leveraging AI and molecular profiling to drive personalized cancer treatment decisions.
Strategic Profile
Pro stress-test →Caris generates revenue through molecular profiling services to healthcare providers, hospitals, and oncologists, charging fees for tests that analyze tumor samples to identify genetic alterations and biomarkers, with key revenue streams including individual test payments, subscription models, and partnerships with pharmaceutical companies. The company is experiencing strong momentum with 2024 revenue of $412.26 million, a 34.67% increase compared to 2023, positioning itself as a high-growth precision medicine player in oncology.
Competitive Landscape
Pro stress-test →Key competitors include Personalis, Oncimmune, GnuBIO, Editas Medicine, and Personal Genome Diagnostics. Caris differentiates through comprehensive molecular profiling combined with proprietary AI/ML algorithms and strong relationships with oncologists and payers in the precision oncology space.
Industry Context
Caris Life Sciences, Inc. operates in Precision Medicine / Molecular Diagnostics / Oncology Genomics.
Key facts
Headquarters: Phoenix, US · Employees: 1,769 · Revenue: $412M (2024 annual); $649M (TTM) · Market cap: $5.8B